Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients

BACKGROUND: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales: Rieker-Schwienbacher, Juliane, Nell, Marja J, Diamant, Zuzana, van Ree, Ronald, Distler, Andreas, Boot, Johan D, Kleine-Tebbe, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658910/
https://www.ncbi.nlm.nih.gov/pubmed/23657148
http://dx.doi.org/10.1186/2045-7022-3-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658910/
https://www.ncbi.nlm.nih.gov/pubmed/23657148
http://dx.doi.org/10.1186/2045-7022-3-16

Ejemplares similares